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Abstract

A

lzheimer’s disease is a progressive neurodegenerative disorder characterized by extracellular
plaque deposits and neurofibrillar tangles. The
plaque deposits are composed primarily of the natively
unfolded amyloid β-peptide (Aβ, containing 39-42
amino acids) that is derived from proteolytic cleavage
of the extracellular segment of the transmembrane
amyloid precursor protein (APP) (1-3). The normal
physiological concentration of Aβ in the brain is less
than 10 nM. However, the critical concentration for Aβ
to aggregate in vitro into amylogenic forms is 110 μM (4, 5). Several hypotheses as to how Aβ aggregates in the brain at concentrations below the critical
nanomolar value include binding/concentration of Aβ
to several orders of magnitude by membranes or organelles, lowering of the critical aggregation concentration
by decreases in pH or presence of metal ions, and
forming covalent adducts between Aβ and oxidative
metabolites (5-7).
Conversion of monomeric Aβ peptide into the aggregated products (oligomers, protofibrils, and fibrils)
in the brain is believed to be the vital event in AD
pathology (8, 9). Fibrils were initially targeted as the
species responsible for neuronal toxicity and cell death
(amyloid cascade). More recently, growing evidence
suggests that much smaller and soluble oligomeric Aβ
species (isolated as dimers, trimers, and tetramers from
various sources such as cells, brain homogenates, and in
vitro aggregation assays) correlate better with severity
of AD than plaques (fibrils) (3, 10-18). However, multiple reports have shown protofibrils, fibrils, and oligomers as toxic species (9, 12, 19-22). Therefore, assembly
of Aβ into either oligomeric or fibrillic assemblies
remains a rational target to reduce Aβ neurotoxicity.
In addition, fibril dissolution agents could be possible
targets for reducing plaque loads in the brain.
Several approaches aimed at reducing production or
clearance of Aβ and its related aggregates in the brain

Neuronal cytotoxicity observed in Alzheimer’s disease
(AD) is linked to the aggregation of β-amyloid peptide
(Aβ) into toxic forms. Increasing evidence points to
oligomeric materials as the neurotoxic species, not Aβ
fibrils; disruption or inhibition of Aβ self-assembly
into oligomeric or fibrillar forms remains a viable
therapeutic strategy to reduce Aβ neurotoxicity. We
describe the synthesis and characterization of amyloid
aggregation mitigating peptides (AAMPs) whose structure is based on the Aβ “hydrophobic core” Aβ17-20,
with R,R-disubstituted amino acids (RRAAs) added into
this core as potential disrupting agents of fibril selfassembly. The number, positional distribution, and
side-chain functionality of RRAAs incorporated into
the AAMP sequence were found to influence the resultant aggregate morphology as indicated by ex situ
experiments using atomic force microscopy (AFM)
and transmission electron microscopy (TEM). For instance, AAMP-5, incorporating a sterically hindered
RRAA with a diisobutyl side chain in the core sequence,
disrupted Aβ1-40 fibril formation. However, AAMP-6,
with a less sterically hindered RRAA with a dipropyl side
chain, altered fibril morphology, producing shorter and
larger sized fibrils (compared with those of Aβ1-40).
Remarkably, RRAA-AAMPs caused disassembly of
existing Aβ fibrils to produce either spherical aggregates
or protofibrillar structures, suggesting the existence of
equilibrium between fibrils and prefibrillar structures.
Keywords: β-Amyloid, Alzheimer’s disease, amyloid
aggregation mitigating peptides, R,R-disubstituted
amino acids, fibrils, spherical aggregates
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Table 1. Mitigators Derived from Modifications of the Aβ Hydrophobic Core (Aβ16-20) and the Ratios Required
To Alter the Aβ Assembly Process
peptide design

ratio (inhibitor/Aβ)

resultant aggregate

method

refs

C-terminal lysine hexamer as disrupting
element (KLVFFK6)

2:1

fibrillar with altered morphology,
nontoxic

TEM, DLS

(43, 44)

KLVFF dendrimer
D-amino acids, KLVFFA

4:1
1:1

spherical aggregates
protofibrils, ill defined aggregates

TEM, AFM
TEM

(46)
(47)

KLVFF-aminoethoxyaceticacid

2:1

glycine spacer (RGKLVFFGR)

2:1

no fibrils

TEM

(48)
(49)

replacement of amide hydrogens with N-methyl
groups

30:1

spherical aggregates

TEM

(50, 51)

replacement of amide bonds with ester bonds
replacement of amide bonds with isostructural
olefin bonds

20:1
substoichiometric or 4:1

nonfibrillar
no inhibition

TEM
ThT

(52)
(53, 54)

β-sheet breakers such as proline

20:1

spherical aggregates

TEM

(55)

disrupted fibril formation, led to disassembly of existing
(preformed) fibrils, and increased cell viability (54).
Although these AAMPs altered the Aβ fibrillization
pathway by inducing different Aβ aggregate morphologies, the processes often required unusually high inhibitor/Aβ molar ratios as shown in Table 1.
Our design of AAMPs is based on the Aβ16-20 hydrophobic core where some natural amino acids were
replaced by the modified analogs (RRAAs). The
R-carbon of the natural amino acid was modified by
introducing a second similar side chain to form RRAAs.
When RRAAs are incorporated in short peptides, they
are known to induce stable extended conformations,
which are ideal for interacting with Aβ through hydrogen bonding as well as by side-chain interactions. When
RRAAs are placed at alternating positions (i, i þ 2, i þ 4),
which positions them on the same hydrogen bonding
face of the extended peptide, this serves to sterically
block the peptide from further hydrogen bonding, hence
disrupting fibril propagation. Also, RRAAs with larger
side chains impose restrictions on peptides that contain
them. Thus, peptides incorporating RRAAs could be
better disrupters of β-sheets than proline-containing
mitigators (54). Peptide mitigators containing RRAAs
with methyl side chains have long been known to disrupt
β-sheets (55). Thus, we hypothesize than mitigators incorporating RRAAs with side chains larger than methyl
groups should be more effective disrupters of β-sheets
and disassemble preformed fibrils.
We previously communicated that at stoichiometric
and substoichiometric concentrations, peptides containing RRAAs alter the Aβ assembly pathway so as to yield
nonfibrillic, nontoxic assemblies (56). Our two AAMPs
(previously denoted as AMY-1 and AMY-2 and having
a hydrophilic lysine tail on the C- or N-terminus, respectively) mitigated Aβ1-40 fibril formation in a way that
ill-defined Aβ1-40 aggregates of different size were produced. When AAMP-1 was injected into hippocampus

are under development (23, 24). These include inhibition
or modulation of proteases involved in the cleavage of
Aβ from the amyloid precursor protein (APP) (25-27),
the use of antibody therapy (through passive immunizations with anti-Aβ antibodies (28-30) and nonantibodybased natural mechanisms) (31-33), small organic molecules or nonpeptides such as inositols, phenols, and
indoles (26, 34-38) and peptides (34). Interest in peptidebased aggregation mitigators of Aβ aggregation has
intensified, because peptides are generally more potent
and display higher specificity of action and fewer toxicological challenges than small organic molecules. A
number of peptide-based amyloid aggregation mitigating peptides (AAMPs) that alter Aβ aggregation kinetics or aggregate morphologies have been developed. All
of these peptide-based mitigators are designed to exploit
the self-interacting Aβ central hydrophobic core (Aβ16-20,
KLVFF) as a recognition element because the assembly
of Aβ oligomers is controlled by initial interaction of
hydrophobic side chains in this central hydrophobic
core.
Several modifications of the hydrophobic core (Aβ16-20)
aimed at designing AAMPs that enhance the disruption
of fibril formation or induce fibril disassembly or both
have been reported (39-47). Murphy and Kessling
added an oligolysine tail to the Aβ16-20 hydrophobic
core that enhanced Aβ aggregation rates resulting in
kinetically trapped, nontoxic fibrillar species (41, 42).
More recently, RG-/-RG amino acid residues added
to the N- and C-termini proved to be effective inhibitors
of fibril formation and protected SH-SY5Y cells (neuroblastoma cell line) from Aβ toxicity (48). Amide backbone modifications of Aβ16-20 core with N-methyl amino
acids (49, 50), ester linkages (51), and isostructural
E-olefin bonds (52, 53) disrupted fibril formation and
induced disassembly of preformed fibrils. Also, Soto
and co-workers designed the peptide LPFFD containing a single proline residue in the Aβ16-20 core, and it
r 2010 American Chemical Society
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Figure 1. Design of amyloid aggregation mitigating peptides (AAMPs) with R,R-disubstituted amino acids (RRAAs) as disrupters of Aβ
assembly. AAMP-0 is the control peptide with no RRAAs. The RRAAs iBu (isobutyl-glycine), Bn (dibenzylglycine), and Pr (dipropylglycine)
are analogs of L-natural amino acids leucine, phenylalanine, and alanine, respectively.

Results and Discussion

of 14-month old APP transgenic mice (TG2576 derived;
Swedish mutation) showing age-dependent accumulation of Aβ in the cerebral cortex and hippocampus, it
showed a tendency to reduce deposition of Aβ assemblies (57). Thus, for optimal use in vivo and improved
systemic bioavailability, the molecular weight and
charge of AAMP-1 should be greatly reduced. The
molecular weight aspect will be addressed in this paper
by evaluating the role and position of individual
RRAAs. The charge component will be addressed in a
separate report because mitigators with a high number
of charged residues (lysine) might not penetrate the CNS
efficiently. The smaller isoform, Aβ1-40, was targeted
because it displays slower aggregation kinetics than the
longer and more toxic Aβ1-42.
Herein, we show that the number and position of
RRAAs in the recognition element (Aβ central hydrophobic core) of the original mitigator AAMP-1 (AMY-1) (56)
is important in determining the effectiveness of the interaction of our AAMPs with Aβ. Also, we further examine
the aggregate inhibition role of each RRAA in AAMP-1
by examination of synthetically derived AAMP-1 analogs
having RRAAs replaced by their natural amino acid
analog (leucine for Dibg, etc). It has been found that the
Aβ1-40-AAMP interaction dictates the microscopically
determined size and morphology differences of the nanoparticles formed. We also show that AAMPs alone do
aggregate slowly to yield exclusively spherical, ill-defined
particles; this latter observation provides some insight into
the mechanism by which the AAMPs disrupt Aβ1-40 fibril
formation. Furthermore, a major finding is that AAMPs
that disrupted fibril formation also led to disassembly of
preformed (existing) Aβ1-40 fibrils.
r 2010 American Chemical Society

Design of Amyloid Aggregation Mitigating Peptide
The central hydrophobic region of Aβ (16-20) is
responsible for Aβ1-40 self-recognition and assembly
that leads to the formation of mature fibrils with diameter 7-10 nm (44). The self-interacting property of Aβ
has been exploited to design disrupters of Aβ1-40 fibrillization. For instance, when RRAAs are incorporated
into a peptide, they are known to induce extended
peptide conformations that are ideal for interaction
with Aβ (58, 59). We hypothesize that peptides containing alternating natural amino acids and RRAAs in a
β-strand (extended) conformation will have one hydrogen
bonding “face” blocked due to the steric hindrance associated with the side chains of RRAAs, and the other face
would remain accessible for additional β-strand hydrogen
bonds. This design strategy (Figure 1) does not prevent Aβ
oligomerization but disrupts additional peptides from
adding to one face of the growing β-sheet, thus changing
the Aβ fibrillization pathway. Previously, we showed that
no fibrils were observed in Aβ1-40-AAMP-1 mixtures
after 4.5 months of incubation at room temperature (56).
In the study at hand, we seek to elucidate the relationship
between the side-chain functionalities of the RRAAs as
well as the positioning and distribution of RRAAs in the
recognition element (KLVFFA) of AAMPs and the
resulting Aβ1-40-AAMP-1 assembly size and morphology. Strategically designed variations of AAMP-1 peptides were synthesized and evaluated (Figure 1). Mitigator
AAMP-0 (KLVFFK6) was used as a control peptide, due
to its lack of RRAAs but similarly designed backbone to
our AAMPs (41, 42).
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When bound to amyloid fibrils, thioflavin T dye
(ThT) undergoes a red shift of its absorbance maximum
from 342 to 442 nm and a characteristic enhanced
fluorescence signal at 482 nm (60, 61). Binding of ThT
dye to Aβ fibrils is complete within 1 min and does not
interfere with Aβ aggregation (61). Thus, ThT fluorescence is commonly used to monitor for the presence of
Aβ fibrils and their rates of formation. It has also been
shown that ThT can bind to certain amorphous aggregatesto produce an increased fluorescence signal (62, 63).
Therefore, increases in ThT fluorescence are insufficient
to monitor Aβ fibril formation/disruption. The combination of complementary methods such as circular
dichroism (CD), AFM, and TEM is needed to probe
mitigation of Aβ1-40 fibril formation by designed inhibitors because such combination can reveal the conformation, size, length, and morphology of resulting
aggregates. We emphasize investigations using highresolution AFM in the present work because of the
unique capability of readily probing early aggregation
products (small oligomers) and providing three-dimensional characteristics of Aβ assembly products (64-69).
Aggregation of Aβ1-40 has been proposed to proceed
via a nucleation-dependent polymerization mechanism
wherein a nucleus is first formed and then grows in size
by addition of monomeric Aβ1-40 (6, 70). Formation of
nuclei from truly monomeric solutions of Aβ1-40 is a
rate-limiting step, and the presence of Aβ1-40 seed nuclei
greatly accelerates aggregation as a result of the presence
of the kinetically more expedient pathway. Thus it is
critical to pretreat Aβ1-40 materials to ensure that the
initial solutions used for mitigator studies possess monomeric Aβ1-40 (71).

Figure 2. Assembly of Aβ1-40 in the presence of RRAA-AAMPs.
Time-dependent ThT fluorescence monitoring of Aβ1-40 assembly
in the presence or absence of the various AAMPs. Fluorescence
(ThT) was set arbitrarily to 100% relative to Aβ1-40. The / denotes
mitigators aged alone.

Aβ1-40 and AAMP-0 is 120% that of Aβ1-40 alone after
3 days of incubation, and 80% of Aβ1-40 alone for
3 months aging times. These observations are consistent
with previous reports describing enhanced Aβ1-40 fibrillogenesis with this material (41, 42).
A significant reduction in Aβ1-40 ThT fluorescence is
observed when Aβ1-40 is aged with an equimolar mixture of RRAA-AAMPs. Mitigators AAMP-1, AAMP-2,
AAMP-3, AAMP-4, AAMP-5, AAMP-7, and AAMP-8
exhibit a reduction of ThT fluorescence between 50%
and 80% relative to that of Aβ1-40 alone, even after 3
months of aging. Peptide mitigator AAMP-6 displayed
a reduced ThT fluorescence of 40% and 20% relative to
Aβ1-40 after 3 days and 3 months aging, respectively.
Comparison of the sequence of AAMP-6 with other
AAMPs that showed reduction in ThT fluorescence
between 50% and 80% relative to the control reveals
the importance of steric effects and position of RRAAs
relative to the recognition element.
Concentration-dependent changes for the disruption
of the Aβ1-40 fibrillization process were examined by
fixing the concentration of Aβ1-40 to 40 μM and adding
selected AAMPs at 4, 40, and 400 μM levels. Samples
were removed at 3 and 7 days of incubation and analyzed
with ThT fluorescence assay. Aggregation of Aβ1-40
into ThT-positive assemblies was disrupted in a concentration-dependent manner (see Supporting Information, Figure S1). The data also reveals that even at
substoichiometric concentration of AAMP-3 (4 μM),
reduction in ThT fluorescence was observed indicating
the disruption of amyloid fibril formation, resulting
possibly in nonfibrillic assemblies. Also, selected AAMPs

Effect of AAMPs on Aβ1-40 ThT Fluorescence
As shown in Figure 2, Aβ1-40 solutions aged in the
presence of equimolar AAMPs display time-dependent
increases in ThT fluorescence, an observation that is
consistent with the formation of aggregates. A small but
measurable increase (3-18%) in ThT fluorescence is
noted in the case of mitigators aged alone, indicating the
formation of a small amount of ThT-active species,
perhaps AAMP aggregates or assemblies.
A significant observation was the decrease in total
ThT fluorescent signal after 3 months of incubation at
room temperature in most of the AAMP-Aβ1-40 mixtures. We speculate that the decreased fluorescence that
is observed results from continuous aggregation of these
mixtures that leads to the formation of larger assemblies
that eventually precipitate out of solution. In addition,
results from the control peptide (AAMP-0) that is
known to enhance Aβ1-40 self-assembly and yield a
network of fibrils (42) were compared with those of our
AAMPs to probe the importance of RRAA presence in
inhibitor make up. The fluorescence of a mixture of
r 2010 American Chemical Society
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Table 2. Wavelength and Corresponding Minimum and Maximum Ellipticities of CD Spectra of AAMPs Alone,
Aβ1-40 Alone, and 1:1 Aβ1-40-AAMP Mixtures (40 μM)a
with Aβ (1:1)
3 days aging
entry

AAMP

λ (nm)

min/max [θ]

λ (nm)

7 days aging
min/max [θ]

λ (nm)

min/max [θ]

1

Aβ1-40

206

-4.89

220

-0.275

198

2

AAMP-0

204

-31.34

219

-1.821

195 (199)

3

AAMP-2

202

-20.88

218

21.10

200 (199)

4
5

AAMP-3
AAMP-4

202
204

-50.18
-18.43

220
221

-4.12
2.82

206 (195)
203 (202)

5.03
-14.66 (-39.86)

λ (nm)
214

min/max [θ]
-14.53

207 (221)

2.4 (3.98)

-9.89 (-36.271)

218 (217)

0.46 (15.83)

0.297 (-29.63)
-7.93 (-22.47)

220 (213)
213 (215)

-3.25 (15.22)
-2.95 (11.83)

6

AAMP-6

202

-50.18

218

-4.41

202 (202)

-8.27 (-40.96)

219 (219)

2.35 (14.12)

7

AAMP-7

202

-25.34

222

-5.85

200 (202)

-11.20 (-22.47)

224 (221)

-0.69 (13.95)

a

Values in parentheses are for AAMPs aged alone after 1 week. Molar ellipticity [θ] units = deg cm2 dmol-1.

200 nm after 1 week of incubation. Also, the minimal
ThT fluorescence observed with AAMPs aged alone
relative to Aβ1-40 suggests that the nanostructures
formed are not β-sheet-rich. We speculate that hydrophobic forces are stronger than hydrogen bonding
forces in the AAMPs in buffered aqueous milieu, and
as a result, spherical AAMP aggregate morphologies
were produced. The small-sized spherical aggregates
formed when AAMP-1 was aged alone for 3 days may
explain the cell toxicity we have reported previously (73).
It is posited that the observed spherical beads of the
AAMPs might act as seeds for Aβ1-40 aggregation,
thereby allowing for the ready formation of Aβ1-40
fibrils. However, this assumes that the AAMP bead-like
aggregates coexist in the presence of monomeric Aβ1-40.
In addition, fibrils of Aβ1-40 were not observed (vide
infra) in the presence of the AAMPs, suggesting that the
possible existence of AAMP bead-like aggregates does
not lead to seeded growth of Aβ1-40 fibrils.

were tested against Aβ1-42, which is more prone to
aggregation and toxic effects. The mitigators tested were
found to disrupt Aβ1-42 assembly similarly as for
Aβ1-40 (see Supporting Information, Figure S2).

Effect of rrAA-AAMPs on the Secondary
Structure of Aβ1-40 as Probed by Circular
Dichroism

To examine the effect of RRAA-AAMPs on Aβ1-40
assemblies, far-UV CD spectroscopy was employed.
The CD spectra of monomeric AAMPs and Aβ1-40
have a characteristic, intense minimum and a maximum
near 200 and 220 nm, respectively, observations that are
consistent with a random coil conformation. After a
week of aging AAMPs alone at 37 °C, the spectrum
found for the random coil conformation of AAMPs remained unchanged, albeit with weaker intensities (Table 2).
Our CD observations for Aβ1-40 (Table 2, entry 1)
reveal that the time course of forming the β-sheet
conformation is consistent with previously reported
β-sheet-rich assemblies (56, 72). The structure of Aβ1-40
incubated alone changed from random coil (monomeric)
to β-sheet after 7 days of incubation (minimum at 214 nm).
In contrast, equimolar mixtures of AAMPs and Aβ1-40
lead to an unusual CD signature (see Supporting Information, Figure S3) having characteristics of both
random coil and β-sheets (Table 2, entries 2-7), these
results are consistent with those from our previous CD
study of Aβ1-40AAMP-1 mixtures (56).

Atomic Force Microscopy Evaluation of
Aggregate Morphologies of Aβ1-40 Aged Alone
and with the Various AAMPs
We used AFM to characterize Aβ1-40 or Aβ1-40AAMP-1 sample aliquots taken at the same time intervals as those used for ThT fluorescence assays. We also
used TEM to confirm AFM observations (see Supporting Information, Figure S5). Images obtained from
AFM topographs of aliquots taken at different aging
times for Aβ1-40 and in presence of AAMP-0 and
AAMP-1 are shown in Figure 3. As expected, fibrils
were the predominant structures observed after 1 week
of aging Aβ1-40 alone (Figure 3A). These fibrils had a
mean height of 4 ( 2 nm, which is smaller than the
reported mean height of about 7-10 nm for mature
Aβ1-40 fibrils (69, 74). The presence of smaller sized
fibrils is an indication that protofibrils and some immature fibrils predominate at the early stage, which is
supported by height distribution analysis that leads to

Atomic Force Microscopy Evaluation of
Aggregate Morphologies of AAMPs Aged Alone
All AAMPs aged alone gave rise to the occasionally
observed spherical, bead-like aggregate with mean
height range of 4-10 nm (see Supporting Information,
Figure S4). The AFM-observed absence of fibrils or
highly organized assemblies is consistent with CD results that exhibit little change in the random coil conformation with maxima around 220 nm and minima at
r 2010 American Chemical Society
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Figure 3. Aggregation of Aβ1-40 with and without AAMPs: (A) fibrils formed by Aβ1-40 alone after 1 week of incubation; (B) height
distribution histogram for panel A; (C) fibril bundles formed by Aβ1-40 alone after 3 months of incubation; (D) height distribution histogram
for panel C; (E) protofibrils formed after 3 days of Aβ1-40 aggregation mitigated by AAMP-0; (F) height distribution histogram for panel E;
(G) fibril network formed after 1 week of Aβ1-40 aggregation mitigation by AAMP-0; (H) height distribution histogram for panel G;
(I) mixture of spherical and linear aggregates formed after 1 week of Aβ1-40 aggregation with mitigation by AAMP-1; (J) height distribution
histogram for panel I; (K) spherical assemblies and protofibrils observed after 3 months of Aβ1-40 aggregation with mitigation by AAMP-1;
(L) height distribution histogram for panel K.

The assembly of Aβ1-40 into fibrils is consistent with
the proposed hierarchical assembly model (HAM model), which predicts that protofilaments predominate at
earlier incubation stages while protofibrils and fibrils
are detected later. The HAM model also predicts that
protofibrils and fibrils will exhibit periodicity, variations
in height, branching, and clumping at various stages of
fibrillization. The unique distribution of fibril morphologies that is observed after 3 months of incubation is
consistent with fibril clumping as predicted by the HAM
model (75, 76).

observation of fibrils with 2-4 nm diameters composing
g60% of total fibrils (Figure 3B). In contrast, bundles
of fibrils (Figure 3C) were the predominant species
observed after 3 months of incubation. An interesting
AFM artifact from a double tip is apparent in
Figure 3C; however the shapes of the fibrils can be well
resolved for this topography frame. The mean height of
the fibrils in the bundles was 11 ( 7 nm, and more than
70% of these bundled fibrils had heights ranging from 4
to 12 nm (Figure 3D) indicating mature fibrils (7-10
nm) had formed.
r 2010 American Chemical Society
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Figure 4. Disruption of Aβ1-40 fibril formation by AAMPs with two RRAAs: (A) globular aggregates formed after 7 days aging Aβ1-40 in
presence of AAMP-2; (B) corresponding height distribution analysis; (C) aggregates formed after 3 months aging Aβ1-40 in presence of
AAMP-2; (D) corresponding height distribution; (E) spherical aggregates formed after 1 week aging Aβ1-40-AAMP-3 mixture; (F) height
analysis for panel E; (G) spherical aggregates after 3 months aging Aβ1-40-AAMP-3 mixture; (H) corresponding height analysis; (I) mixture of
spherical aggregates and protofibrils formed after 7 days aging Aβ1-40 in the presence of AAMP-4; (J) corresponding height distribution
analysis for panel I; (K) after 3 months aging Aβ1-40 in the presence of AAMP-4; (L) matching height distribution histogram.

Importance of Using rrAAs as Disrupting
Elements: Effect of Three rrAAs on Aβ1-40
Fibril Formation

heights (Figure 3F,H). In contrast, mixtures of protofibrils and spherical aggregates (Figure 3I) with a mean
height of 10 ( 8 nm were observed with AAMP-1 after 1
week of incubation, and rod-like structures (Figure 3K)
were formed after 3 months with a slight increase in
mean height as displayed in Figure 3J,L.
The AAMP-0 peptide (no RRAAs) was used as a
control sample for evaluating the effects of RRAAs in
the mitigator backbone. This peptide (AAMP-0) was
shown previously to enhance the rate of aggregation of
Aβ1-40 and give rise to dense networks of fibrils (42).
The enhanced Aβ1-40 aggregation rates may also lead to

The significance of RRAAs in disrupting fibril formation was evaluated by aging equimolar mixtures of
Aβ1-40 with AAMP-0 (no RRAAs) and AAMP-1 (with
RRAAs). For instance, after 3 days of aging Aβ1-40AAMP-0 mixtures, protofibrils (Figure 3E) with mean
height of 9 ( 6 nm were the main structures observed. A
dense network of fibrils (Figure 3G) with mean height of
9 ( 3 nm was observed after 1 week of aging. The height
histograms possess time-dependent increases in fibril
r 2010 American Chemical Society

614

DOI: 10.1021/cn100045q |ACS Chem. Neurosci. (2010), 1, 608–626

Article

pubs.acs.org/acschemicalneuroscience

lateral features result from a convolution of the tip
shape.
The disruption of fibril formation by AAMPs with
two RRAAs is an important finding in that these
AAMPs portrayed the same or better disruptive properties as the original AAMP-1 peptide with three RRAAs.
The more interesting aspect of their disruption is the
relation between size and morphology of the particles
formed and the side chain functionality of incorporated
RRAAs. Larger particles with similar morphology were
formed from Aβ1-40 aggregation mitigated by AAMP-2
and AAMP-4, compared with AAMP-3. The difference
in observed heights could be attributed to the side chain
functionality of the RRAAs incorporated in AAMP-2
(Dbg and Dpg), AAMP-3 (Dibg and Dpg), and AAMP4 (Dbg and Dibg). Notably, Dbg (aromatic)-containing
AAMPs (AAMP-2 and AAMP-4) formed larger particles compared with AAMP-3 without Dbg. Thus incorporation of the additional aromatic side chain in
Dbg-containing AAMPs may play a role in determining
the size and morphology of the resultant nanoparticles,
because aromatic residues are believed to supply energy,
order, and directionality (77, 78) to the Aβ assembly
process during fibril formation through aromatic sidechain stacking interactions.
Hydrophobic or steric effects from RRAAs may also
contribute to the size and morphology of structures
formed. For instance, larger spherical aggregates with
a few protofibrils/fibrils were formed with AAMP-4
compared with mainly spherical aggregates for AAMP-2.
The different sizes and morphologies of particles formed
can thus be related to the combination of the RRAAs
used in each AAMP. They both have aromatic Dbg and
a different second RRAAs (Dpg and Dibg for AAMP-2
and AAMP-4, respectively). Thus, steric or hydrophobicity differences between Dpg (n-side chains) and Dibg
(branched side chains) has influenced the size and morphology of the assemblies formed.
Positioning of RRAAs relative to each other in the
AAMP sequence could influence the size and morphology of assemblies formed. One of the ways to induce
extended peptide conformations required for the interaction with Aβ in short model peptides is to use RRAAs
with larger side-chain groups. For instance, smaller particles were formed by Aβ1-40 mitigation by AAMP-3
compared with either AAMP-2 or AAMP-4. The two
RRAAs are in an i, i þ 2 orientation in AAMP-2 and
AAMP-4 compared with an i, i þ 4 arrangement in
AAMP-3. Other examples of i, i þ 2 design mitigators
that were designed by replacement of amide backbone
include N-methyl groups, ester linkages, and isostructural
E-olefins, all of which were shown to mitigate fibril
formation (49, 51, 52). Thus placement of the disrupting
elements on the same hydrogen bonding face is more
crucial for the mitigators to disrupt fibril formation than

thicker (taller) fibrils compared with Aβ1-40 fibrils from
its solitary incubation. The structural design for AAMP-0
and our AAMPs are similar except for RRAAs incorporated in the latter (for example, Dbg for Phe, etc). The
peptide mitigator AAMP-1 was previously shown to
block Aβ1-40 fibrillization even after 4.5 months of incubation at room temperature (56). The different aggregate
morphology observed for Aβ1-40 aggregation mitigated
by AAMP-0 (fibrils) compared with RRAA-containing
AAMP-1 (mixture of spherical aggregates and rod-like
structures) reinforces the contrast in using RRAA-containing AAMPs to disrupt fibril formation. The results
for AAMP-1 with further characterization of the sizes
and morphologies of nanostructures formed at different
stages of aggregation using high-resolution AFM are
presented in Figure 3I,K. The AAMP-1 analogs were
screened for their ability to disrupt Aβ1-40 assembly compared with the original mitigator (AAMP-1).

Effects of AAMPs Containing Two rrAAs on
Aβ1-40 Fibril Formation

When AAMP-1 analogs with two RRAAs were aged
with equimolar Aβ1-40, assemblies with different heights
and morphologies were formed, and the size/morphology type observed being related to the side-chain
functionality of the RRAAs used. Spherical aggregates
(Figure 4A) with mean heights of 8 ( 4 nm (60% of the
particles with height range of 4-8 nm, Figure 4B) were
observed after 1 week of aging Aβ1-40-AAMP-2 mixtures. The spherical morphology of the aggregates did
not change after 3 months incubation, but aggregates
were observed to coalesce, forming in some cases aggregate strings (Figure 4C). The only significant change
was the slight increase in mean heights (9 ( 4 nm) as
shown by height distribution analysis (Figure 4D).
Compared with AAMP-2, smaller sized spherical aggregates (Figure 4E) with mean height 2 ( 1 nm were
formed from co-incubation of Aβ1-40 with equimolar
AAMP-3. The same morphology was observed after 3
months incubation (Figure 4G) but with a larger mean
height (4 ( 2 nm) as shown by AFM cursor analysis
(Figure 4F,H). Mixtures of ill-defined aggregates and
protofibrils/fibrils visible in the background) with mean
height of 18 ( 9 nm (Figure 4I) formed after 1 week of
Aβ1-40 mitigation by AAMP-4 compared with mostly
spherical particles observed after 3 days of incubation.
After 3 months of incubation, the mean height of the
particles (Figure 4K) more than doubled (43 ( 25 nm)
with maximum height spanning to 1 μm as shown in
Figure 4J,L. The particles for AAMP-4 appear to have a
triangular shape attributed to tip-sample convolution.
The convolution results from imaging very tiny, sharp
asperities on the sample surface using a much larger tip,
thereby yielding a regular printed artifact in the image.
The height information will be reliable; however the
r 2010 American Chemical Society
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Figure 5. Topographic AFM images showing disruption of Aβ1-40 fibril formation by AAMPs with one RRAA: (A) view of nonfibrillic assemblies
formed after 1 week Aβ aggregation mitigation by AAMP-5; (B) corresponding height distribution; (C) view after 3 months mitigation by AAMP-5;
(D) height analysis for panel C; (E) progressive AFM view of rod-like fibrils detected after 1 week of aging Aβ1-40-AAMP-6 mixture; (F) corresponding
height distribution; (G) view after 90 days of aging Aβ1-40-AAMP-6 mixture; (H) height distribution analysis for panel G; (I) view of spherical and
protofibrils/fibrils (background) formed by Aβ1-40-AAMP-7 mixture after 1 week aging; (J) corresponding height analysis; (K) view after 90 days aging
of Aβ1-40-AAMP-7 mixture; (L) height analysis for panel K; (M) view of spherical particles formed by Aβ1-40 aggregation mitigation by AAMP-8;
(N) corresponding height distribution; (O) view after 3 months aggregation mitigation by AAMP-8; (P) height analysis for panel O.
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their arrangement. In addition, based on our findings with
RRAAs, the number of other disrupting elements reported
such as N-methylated derivatives and ester linkages could
be reduced without affecting their disruptive properties.

Effects of AAMPs with One rrAA on Aβ1-40
Fibril Formation

The role of AAMPs with only one RRAA in the
mitigation of Aβ1-40 aggregation was examined by
aging Aβ1-40 in the presence of equimolar amounts of
AAMP-5 (Dibg), AAMP-6 (Dbg), and AAMP-7 (Dpg).
Globular particles were observed to form with AAMP-5
(Figure 5A), which were stable (no fibrils) after 3 months
of aging (Figure 5C). Height analysis shows that the
percentage of the particles with heights ranging from 4
to 6 nm increased from ∼30% for 1 week of incubation
to over 50% after 3 months of aging (Figure 5B,D). Coincubation of Aβ1-40-AAMP-6 mixture produced protofibrillar structures and rod-like fibrils (Figure 5E)
after 1 week. The protofibrils (Figure 5G) observed
after 3 months of incubation had increased in mean
height as displayed by height analysis showing a 2-fold
increase in the percentage of particles with heights of
4-6 nm compared with after 1 week (Figure 5F,H).
Aging of Aβ1-40 with equimolar amounts of AAMP-7
resulted in mainly spherical particles after 3 days. However, a mixture of spherical aggregates and fibrils/protofibrils (Figure 5I) in the background were detected
after 1 week of incubation with over 50% of the particles
with heights ranging from 1 to 10 nm (Figure 5J). After 3
months of aging, the morphology of the particles
(Figure 5K) did not change, but their sizes increased
as shown by the increase in the percentage of particles
with larger heights (Figure 5L). Spherical aggregates
(Figure 5M) with mean heights of 10 ( 5 nm were formed
from Aβ1-40 mitigation by AAMP-8 after aging for 1
week. Surprisingly, after 3 months, spherical aggregates
(Figure 5O) observed earlier have increased in size to
greater than a micrometer in some cases, as shown by
AFM height analysis (Figure 5N,P).
Results from Aβ1-40 mitigation by AAMPs with one
RRAA further confirms that side chain functionality of
incorporated RRAAs influences the size and morphology of the resulting nanoparticles. For example, the different morphology of the particles observed in AAMP-5
compared with AAMP-6 is because of the steric difference between the RRAAs incorporated: spherical aggregates formed with AAMP-5, which incorporates the
more sterically hindered Dibg (isobutyl side chains),
compared with rod-like fibrils in AAMP-6, which contains the less sterically hindered Dpg (n-propyl side
chains). In addition, the size and morphology of fibrils
formed by AAMP-6 were different from those of Aβ1-40
alone. Fibrils formed by AAMP-6 had larger mean
heights (7 ( 3 nm) and smaller lengths (e1 μm in length)
r 2010 American Chemical Society

Figure 6. Disassembly of Aβ1-40 preformed fibrils. ThT
fluorescence of Aβ1-40 fibril disassembly by the various AAMPs
after 24 h incubation at 37 °C while shaking.

compared with mature Aβ1-40 fibrils, which were smaller in mean height (4 ( 2 nm) and several micrometers in
length. The short fibril lengths suggest lateral interactions of protofilaments rather than the intertwining
commonly identified during amyloid fibril formation,
which can also be because of a slower growth rate of
protofilaments by elongation and dissociation of monomers. The branching and polymorphic nature of the
fibril lengths observed may have been caused by the
interactions between protofibrils of unequal lengths (76).
Positioning of the RRAAs relative to KLVFF core
sequence also influences the morphology of the resulting
nanoparticles. The core sequence KLVFF has been
shown to be critical for the inhibitor peptide to interact
with Aβ. Thus, mitigators with RRAAs placed outside
this core sequence should have less influence on the
interaction with Aβ compared with mitigators with
RRAAs incorporated into this region. An example is
the different morphology of particles formed from Aβ1-40
mitigation by AAMP-8 (nonfibrillic assemblies) with
Dpg incorporated in the KLVFF core (KLDpgFFAK6)
compared with AAMP-6 (rod-like fibrils) with Dpg
outside the KLVFF core (KLVFFDpgK6). We speculate that the AAMPs with RRAAs incorporated into
the binding motif resulted in increased side-chain to
side-chain hydrophobic interactions with the homologous core of Aβ. Thus, blocking one face from interchain hydrogen bonding disrupts the Aβ aggregation
pathway.
Interestingly, Aβ1-40 aggregation mitigated by AAMP7 with aromatic Dbg yielded spherical aggregates after
3 days of aging. However, after 1 week of incubation a
mixture of spherical particles and protofibrils/fibrils in
the background with very different morphology relative
to Aβ fibrils were formed. This was an unexpected result
since it was predicted to disrupt formation of fibrillar
structures similar to AAMP-5, which incorporates Dibg.
A plausible explanation for the different morphology of
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Table 3. Effect of Various AAMPs on Aβ1-40 Disassembly
aggregate type after 24 h
entry
1

mitigators

R,R-disubstituted amino acid

2

AAMP-0

3

AAMP-1

dominant structures

Dibg, Dbg, Dpg

mean height (nm)

isolated structures

mean height (nm)

6(3

fibrils

Aβ1-40

fibrils

5(3

spherical

spherical

6( 3

fibrils

11 ( 6

6(2
12 ( 5

4

AAMP-2

Dbg, Dpg

spherical

3(1

fibrils

5

AAMP-3

Dibg, Dpg

spherical

8(5

fibrils

8(3

6
7

AAMP-4
AAMP-5

Dbg, Dibg
Dibg

spherical
spherical

11 ( 8
5(4

fibrils
fibrils

5(3
5(2

8

AAMP-6

Dpg

fibrils

7(2

spherical

5(3

9

AAMP-7

Dbg

spherical

11 ( 6

fibrillar

5(3

10

AAMP-8

Dpg

spherical

11 ( 8

fibrillar

9(5

incubation are presented in Figure 6 as %ThT fluorescence relative to that of Aβ1-40 fibrils.
The general reduction in ThT fluorescence Aβ1-40AAMP mixtures mixtures relative to that of Aβ1-40 alone
indicates that fibril disassembly occurred. For instance,
AAMP-1, AAMP-2, AAMP-3, and AAMP-4 reduced
Aβ ThT fluorescence by nearly 80%. This is comparable
to the disassembly of Aβ1-40 fibrils reported for β-sheet
breaker peptide (LPFFD) (54), RGTFEGKF peptide (81), and N-methylated peptides (49-51), although
this was at lower AAMP ratios. Coincidentally, these
same mitigators disrupted Aβ1-40 fibril formation by a
similar degree. The other AAMPs (AAMP-0 and Dpgcontaining AAMP-6) reducedAβ1-40 ThT fluorescence
by ∼20%. Interestingly, these were the mitigators that
only altered fibril morphology when aged with monomeric
Aβ1-40. The reduced fluorescence observed could also
be from inhibitor molecules displacing ThT molecules
bound to the preformed fibrils leading to false positive
results for fibril disassembly (63, 82). Thus, AFM and
TEM were used to probe the morphology of the Aβ1-40
disassembly products.

particles formed by the two mitigators is the aromatic
nature of Dbg versus Dibg. This could be due to the
enhanced aromatic-stacking interactions asserted by
the extra aromatic residue. After 3 days of incubation,
AAMP-4 and AAMP-7 disrupted fibril formation.
However, after 1 week of incubation, a mixture of
spherical particles and protofibrils/fibrils were observed.
This indicates that higher ratios of AAMP to Aβ1-40 are
needed to prevent fibril formation.

Aβ1-40 Fibril Disassembly
Several laboratories have reported that a dynamic
equilibrium exists between Aβ1-40 monomers/dimers
and fibrils (54, 79). Thus, a viable strategy to mimic
possible dissolution of plaque deposits commonly present in the brains of patients with AD is to screen for
compounds that can bind to preformed fibrils, shifting
the equilibrium toward prefibrillar species. Soto (54, 80)
and Meredith (49, 50) have shown that peptides that
incorporate proline (β-sheet breaker) and N-methylated
amino acids have the ability to disassemble mature
Aβ1-40 fibrils (49, 50, 54). The design of N-methylated
peptides and our RRAA-containing AAMPs are similar
in that both were designed to block one hydrogenbinding face thus preventing β-sheet stacking and extension. Therefore, we hypothesized that RRAA-containing AAMPs should also disassemble preformed
fibrils because of the more bulky side chains, compared
with the methyl group in N-methylated peptides.

Size and Morphology of Structures Formed from
Disassembly of Preformed Fibrils by Various
AAMPs
Results for the disassembly of preformed fibrils by
24 h incubation with certain AAMPs are summarized in
Table 3. A topographic AFM image of Aβ1-40 taken
after 6 days aging showed a dense network of fibrils
(Figure 7A) with a mean height of 6 ( 3 nm. The height
analysis (Figure 7B) reveals the maturity of the fibrils
formed, with more than 60% of the fibrils having
heights between 4 and 8 nm, consistent with the height
of mature fibrils (7-10 nm).
Topographic AFM images of Aβ1-40 fibrils disassembled by AAMP-0 (no RRAAs) exhibit reduced surface coverage of fibrils and a few spherical particles
consistent with the 20% reduction in ThT fluorescence
observed relative to that of Aβ1-40. Also, this is consistent

Aβ1-40 Fibril Disassembly as Judged by
Thioflavin T Fluorescence
To assess the ability of AAMPs to disassemble preformed fibrils, Aβ1-40 was aged for 6 days at 37 °C while
shaking. The mature fibrils that formed were mixed with
the various AAMPs at 1:1 molar ratio (40 μM final
concentration) and incubated while shaking for 24 h.
The extent of disassembly was measured by ThT fluorescence. Results of ThT fluorescence for the disassembly
of preformed fibrils by the various AAMPs after 24 h
r 2010 American Chemical Society
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pared with AAMP-1. In addition to observing nonfibrillic
assemblies, isolated protofibrils (beaded morphology)
and fibrils (smooth) were detected in these mixtures. The
height distribution reveals that most of the particles
formed were less than 10 nm in height (Figure 7B,D,F,
H,J,L). Coincidentally, these same AAMPs showed up
to 80% reduction in ThT fluorescence. Thus, RRAAs
play a role in disassembly of preformed fibrils as seen
from fibrils being the predominant species formed with
AAMP-0 (no RRAAs) compared with nonfibrillic assemblies formed with RRAA-containing AAMPs, for
example AAMP-1, AAMP-2, etc. This is consistent

with previous reports that AAMP-0 does not induce
fibril disassembly. The height distribution shows a distribution similar to that of Aβ1-40 fibrils (Figure 7D). In
contrast, RRAA-containing AAMPs induced disassembly of preformed fibrils to form nonfibrillic assemblies
and isolated protofibrils/fibrils. Nonfibrillic assemblies
and a few isolated fibrillar structures were the main
structures observed from Aβ1-40 fibril disassembly by
AAMP-1 (Figure 7E), with three RRAAs. The same
result (nonfibrillic assemblies) was also observed
with AAMP-2 (Figure 7G), AAMP-3 (Figure 7I), and
AAMP-4 (Figure 7K), incorporating two RRAAs com-

Figure 7. Disassembly of Aβ1-40 preformed fibrils: (A) Aβ1-40 fibrils; (B) corresponding histogram; (C) fibrils/protofibrils formed as a result
of fibril disassembly after 24 h exposure to AAMP-0; (D) height analysis for panel C; (E) spherical aggregates induced by 24 h exposure to
AAMP-1 fibril to induce disassembly; (F) height histogram analysis for panel E; (G) spherical particles formed after 24 h disassembly by
AAMP-2; (H) height analysis for panel G; (I) spherical aggregates from disassembly by AAMP-3 after 24 h; (J) corresponding height analysis;
(K) spherical assemblies formed from fibril disassembly by AAMP-4 after 24 h; (L) height histogram for panel K.
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cles for AAMP-7 and AAMP-8, were shorter in length
and in some with beaded morphology compared with
Aβ1-40 fibrils. Also, the protofibrils/fibrils formed by
AAMP-6 were shorter and with beaded morphology but
with similar height distribution (Figure 8D) and mean
height (Table 2) compared with Aβ1-40 fibrils. This
suggests that these AAMPs induced partial disassembly
or fibril breakage of preformed fibrils forming protofibrils (beaded morphology) and short fibrils with mean
heights matching those of Aβ1-40 fibrils (Table 2). The
partial disassembly of Aβ1-40 preformed fibrils and
disruption of fibril formation by AAMP-6 shows that
positioning of RRAAs relative to KLVFF influences
both disassembly and assembly processes.
The observed disassembly of preformed fibrils into
either oligomeric or prefibrillar particles (precursors of
fibril formation) indicates a shift in equilibrium. It has
been shown that fibrils elongate by monomer addition
to the fibril ends. Therefore, disassembly of fibrils suggests
that AAMP possibly binds at the fibril end, which shifts
the thermodynamic equilibrium back toward oligomeric
(AAMP-5, AAMP-7, and AAMP-8) and protofibrillar
(AAMP-6) assemblies. Even in cases where fibrils/protofibrils were observed, the surface coverage was profoundly reduced compared with the dense network of

with the ThT fluorescence observations. Significant also
was the increased heights of isolated fibrils formed by
disassembly of preformed fibrils by RRAA-containing
AAMPs compared with either Aβ1-40 fibrils or AAMP-0
(Table 1). This may suggest that RRAAMPs bind to
fibrils or cause the fibrils to coalesce resulting in increased heights.
Disassembly by 24 h incubation of preformed fibrils
with AAMPs having one RRAA resulted in mixtures of
spherical particles and protofibrils/fibrils. For instance,
spherical particles and isolated fibrils/protofibrils were
formed from Aβ1-40 fibril disassembly by AAMP-5
(Figure 8A), AAMP-7 (Figure 8E), and AAMP-8
(Figure 8G). In contrast, disassembly of preformed
fibrils by AAMP-6 formed mainly fibrillar structures
(Figure 8C) that exhibited a beaded morphology and a
periodicity characteristic of protofibrils.
Larger spherical particles were formed from disassembly by AAMP-7 and AAMP-8 compared with
AAMP-5, as shown by the height analysis (Figure 8B,
F,H). Surprisingly, similar trends were observed for the
assembly of Aβ1-40 in the presence of these AAMPs and
thus aromaticity (AAMP-7) and steric effects (AAMP-8)
play a part in the disassembly process as well. Isolated
protofibrils/fibrils, observed along with spherical parti-

Figure 8. Disassembly of Aβ1-40 preformed fibrils after 24 h exposure to certain AAMPs: (A) spherical aggregates induced by AAMP-5 fibril
disassembly; (B) height histogram analysis for panel A; (C) fibrils/protofibrils formed as a result of fibril disassembly by AAMP-6; (D) height
analysis for panel C; (E) spherical aggregates from disassembly by AAMP-7; (F) corresponding height analysis; (G) spherical assemblies
formed from fibril disassembly by AAMP-8; (H) height histogram for panel G.
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β-sheet content. Based on our design strategy, we hypothesized that AAMPs bind Aβ1-40 and block one face of
aggregation, which affects the formation of hydrogenbonding interchains and takes Aβ1-40 fibrillogenesis off
the normal aggregation pathway. This favors hydrophobic interactions over hydrogen bonding and results
in nonfibrillic assemblies. In addition, the absence of
fibrillar structures in aged Aβ mitigator solutions is
evidence that supports a mechanism of growth by coalescence and conversion into β-sheet-rich assemblies. This
differs in comparison to a nucleation-dependent mechanism, where inhibitor would act as seed and enhance
aggregation kinetics leading primarily to formation of
fibrils; since such fibrils were not the major species
observed in most of the experiments.
Based on recent reports that show oligomers to be
more toxic than fibrils, the spherical particles formed
from our Aβ assembly mitigation experiments are also
expected to be toxic. However, not all oligomers are
toxic, probably because of the size distribution over a
wide molecular weight range (less than 10 kDa to greater
than 100 kDa), and with structural polymorphism observed even with oligomers of similar sizes. This indicates that the size, morphology, and on/off pathway are
possible factors that determine the toxicity of oligomers.
We hypothesize that the spherical Aβ-inhibitor aggregate is an off-pathway product and very likely is different morphologically than normal Aβ oligomer
aggregate and hence is less toxic. This hypothesis is
supported by reports that show inhibitors that alter Aβ
aggregation kinetics form morphologically different
fibrils that are less toxic.
Furthermore, a possible application of our findings is
that RRAAs can be used to control neuronal toxicity
from Aβ species. Neurotoxicity is believed to be a result
of aberrant interactions between cellular components,
such as membranes, proteasomes, or molecular chaperons, and solvent-exposed hydrophobic surfaces of oligomeric assemblies. The size of aggregates affects these
interactions, with the highest toxicity resulting from
aggregates with a high surface area to volume ratio
(89-91). This explains why fibrils and, to some extent,
large oligomers are not very toxic compared with small
oligomeric assemblies. We showed that position, distribution, and side-chain functionality of RRAAs incorporated in the binding core affects the size of the
resulting assemblies. Thus, we can use RRAAs to influence the desired size of aggregates formed, in hopes of
controlling neurotoxicity. This hypothesis will be tested
as part of the future work in cellular systems.

Aβ1-40 fibrils, suggesting that some amount of disassembly occurred.

Conclusions
Our study validates the use of RRAAs as disrupting
elements when incorporated into the KLVFF motif for
designing amyloid aggregation mitigating peptides, as
indicated by the absence of fibrillic assemblies in comparison to the control peptide (AAMP-0). We showed
that the side-chain interactions associated with the
various RRAAs are important in disrupting fibril formation. A major finding was that the mitigators possessing one RRAA were as effective in disrupting Aβ1-40
fibril formation as the mitigators having two or three
RRAAs. Thus, these findings support our efforts to
reduce the overall molecular weight of the peptide
without affecting its efficacy for optimal in vivo use
and improved systemic bioavailability.
Interestingly, we found that the mitigators that disrupted fibril formation also disassembled fibrils. This
suggests the existence of an equilibrium between Aβ1-40
monomers/dimers and fibrils. Molecular dynamic simulations have been employed to study the mechanism of
how these mitigators interact and disassemble fibrils
(80, 83, 84). Recently, Yassmine et al. showed through
simulation the disassembly of Aβ16-22 protofibrils by
N-methylated inhibitors (85). They reported that Nmethylated inhibitors interact with the protofibril by
both lateral and longitudinal association, thereby disrupting the β-sheet extension and its lateral association
into layers. More importantly, they showed that the
inhibitor peptides intercalate and possibly sequester the
Aβ peptides, which we believe to be the mode of action
for our designed RRAA-AAMPs in disrupting Aβ1-40
fibrillogenesis. The substoichiometric inhibition of fibril
formation by selected mitigators is further evidence for
this mode of action. Based on Tycko’s structural model
(86), we hypothesize that the interaction of RRAAAAMPs with Aβ1-40 at the region 17-20 disrupts the
“bend” segment between the two β-strands, affecting
β-sheet extension and packing during fibril formation.
More recently, the fibril growth mechanism has been
shown in computer simulations and experimental data
to proceed via two steps (87, 88). The initial step is
coalescence driven by the rapid formation of nonspecific
hydrophobic interactions. This is followed by a conformational conversion to ordered β-sheet structures because of the slow formation of highly directional,
interchain hydrogen bonds. Competition between hydrophobic interactions and hydrogen bonding is important
for determining the morphology of aggregates that are
formed. Aging conditions can affect hydrogen-bonding
interactions to yield both fibrillar and nonfibrillar assemblies with different morphologies but with the same
r 2010 American Chemical Society
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Samples of AAMPs were prepared from 9H-fluoren-9ylmethoxycarbonyl (Fmoc) amino acids using solid-phase
peptide synthesis (SPSS) on PAL-PEG-PS resin or Rink
amide ChemMatrix resin. Couplings, Fmoc removal, and
resin cleavage were carried out using previously described
methods (92-94). The crude peptides were purified by reversed-phase HPLC using a 10% to 70% B linear gradient
over 60 min [Waters C4 100 Å column using solvent A (water
and 0.1% trifluoroacetic acid, TFA) and solvent B (acetonitrile and 0.1% TFA)]. The purity of the peptides was
evaluated by analytical HPLC, and the identity of the peptides
was assigned from masses determined by ESI-MS. The percent peptide content was established by amino acid analysis.

surface three times with 40 μL of deionized water. An Agilent
5500 atomic force microscope equipped with PicoScan v5.3.3
software was used for surface characterizations (Agilent Technologies AFM, Inc. Chandler, AZ). Cantilevers (NSL-20)
from Nanoworld Holdings AG (Schaffhausen, Switzerland)
were used for imaging samples by tapping mode in air. The
cantilever was driven to oscillate at 185 ( 10 kHz for ambient
AFM characterizations. The mean height is obtained by taking
multiple cursor measurements of the thickness of the fibrils
throughout several representative images. The distribution of
heights is presented as a histogram for each AFM view. The
individual plots shown for the surface topography of the
various samples are representative views of the morphologies
observed for multiple areas of the samples.

Peptide Monomerization

Transmission Electron Microscopy

Peptide Synthesis

Lyophilized Aβ1-40 was pretreated to form monomeric
solutions following our previously published protocol (71).
Briefly, Aβ1-40 was dissolved in neat TFA at 1 mg mL-1 and
sonicated for 10-20 min. Removal of TFA using a Centrivac
yielded a pale yellowish residue, and it was redissolved in 1 mL
of hexafluoroisopropanol (HFIP) at 1 mg mL-1 and then
incubated at 37 °C for 1 h. Removal of HFIP yielded a white
powder that was redissolved in HFIP and split into 0.25 mg
fractions based on the assumption that the mass of Aβ1-40
was 50% at this point in the preparation. The fractions were
incubated for 1 h, at which time the HFIP was removed by
vacuum, and the resulting white powder was lyophilized
overnight. The lyophilized white powder was dissolved in a
2  10-3 M NaOH/PBS (100 mM, 300 mM NaCl, pH 7.4)
mixture at a 1:1 ratio and then centrifuged for 20 min at 13 000
 g; these solutions were used immediately in aggregation
assays. The supernatant was subjected to amino acid analysis
to determine the net peptide content of the solutions.

Samples for TEM analysis were prepared by placing
sample droplet onto a carbon support Cu-coated grid (EMS
400-CU) for 1-2 min. Excess sample was absorbed into a
filter paper, placed onto a droplet of water, and then stained
using 2% uranyl acetate droplet. The grid was cleared of
excess uranyl acetate, labeled with its experimental designation, and then stored in a Petri dish. Images were recorded
using a JEOL 100 CX TEM, 80 kV accelerating voltage.

Supporting Information Available
Additional data including extended figures. This material
is available free of charge via the Internet at http://pubs.
acs.org.

Author Information
Corresponding Author
*
Jayne C. Garno: phone 225-578-8942; e-mail jgarno@lsu.edu;
mailing address Chemistry Department, Louisiana State University,
232 Choppin Hall, Baton Rouge, LA 70803.
Author Contributions
Experiment design, peptide synthesis and CD characterizations were accomplished by C.K.B., K.R.F., and R.P.H.
Characterizations with AFM were accomplished by J.N.N.
and C.K.B. with instruments and materials provided by J.C.
G. Data analysis and writing were completed by C.K.B. with
editing and analysis by all of the authors.

Thioflavin T Aggregation Assays
Monomeric Aβ1-40 prepared as described in the peptide
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phosphate-buffered saline (PBS) buffer (50 mM, 150 mM
NaCl, pH 7.4). For ThT results from longer time points of 3
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stock solution in water, and 180 μL of PBS were mixed in a
low-binding, 96-well plate with a transparent bottom
(Corning incorporated cat. no. 3651). A ThT fluorescence
emission spectrum was acquired at 480 nm (excitation at 440
nm) using a fluorescence plate reader (BMG, LABTECH).
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Atomic Force Microscopy

A sample aliquot of 10 μL was diluted 2-fold and adsorbed
onto the surface of freshly cleaved mica(0001) for 5-10 min
(Ruby muscovite mica, S&J Trading Co., NY). The remaining
excess liquid was absorbed onto a filter paper or lab tissue.
Salts and excess unbound peptide were removed by rinsing the
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